CN101754681A - 治疗用吡唑并萘啶衍生物 - Google Patents

治疗用吡唑并萘啶衍生物 Download PDF

Info

Publication number
CN101754681A
CN101754681A CN200880025152A CN200880025152A CN101754681A CN 101754681 A CN101754681 A CN 101754681A CN 200880025152 A CN200880025152 A CN 200880025152A CN 200880025152 A CN200880025152 A CN 200880025152A CN 101754681 A CN101754681 A CN 101754681A
Authority
CN
China
Prior art keywords
alkyl
compound
aryl
animal
gaba
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880025152A
Other languages
English (en)
Chinese (zh)
Inventor
艾伦·P·卡普兰
瓦沙·古普塔
扬·W·F·瓦斯利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helicon Therapeutics Inc
Original Assignee
Helicon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helicon Therapeutics Inc filed Critical Helicon Therapeutics Inc
Publication of CN101754681A publication Critical patent/CN101754681A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN200880025152A 2007-06-08 2008-06-06 治疗用吡唑并萘啶衍生物 Pending CN101754681A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94300007P 2007-06-08 2007-06-08
US60/943,000 2007-06-08
PCT/US2008/066211 WO2008154447A1 (en) 2007-06-08 2008-06-06 Therapeutic pyrazolonaphthyridine derivatives

Publications (1)

Publication Number Publication Date
CN101754681A true CN101754681A (zh) 2010-06-23

Family

ID=40130166

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880025152A Pending CN101754681A (zh) 2007-06-08 2008-06-06 治疗用吡唑并萘啶衍生物

Country Status (12)

Country Link
US (2) US7858614B2 (enExample)
EP (1) EP2166853B1 (enExample)
JP (1) JP2010529145A (enExample)
KR (1) KR20100036306A (enExample)
CN (1) CN101754681A (enExample)
AU (1) AU2008261803A1 (enExample)
BR (1) BRPI0812369A2 (enExample)
CA (1) CA2689934A1 (enExample)
ES (1) ES2483728T3 (enExample)
IL (1) IL202287A0 (enExample)
MX (1) MX2009013197A (enExample)
WO (1) WO2008154447A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106810550A (zh) * 2017-01-10 2017-06-09 湖南华腾制药有限公司 一种萘啶衍生物的制备方法
CN117430602A (zh) * 2023-09-26 2024-01-23 爱斯特（成都）生物制药股份有限公司 一种制备6-卤代-4-羟基[1,5]萘啶-3-甲酸酯及其衍生物的方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008261888A1 (en) * 2007-06-08 2008-12-18 Helicon Therapeutics, Inc. Therapeutic pyrazoloquinoline urea derivatives
EP2627655B1 (en) * 2010-10-14 2015-09-16 Dart Neuroscience (Cayman) Ltd FUSED 3-OXO-PYRAZOLO[4,3-c]PYRIDINE COMPOUNDS AS GABAA MODULATORS
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
CN208806957U (zh) * 2015-10-23 2019-04-30 哈曼国际工业有限公司 双非对称压缩驱动器
UA125800C2 (uk) 2017-06-30 2022-06-08 Баєр Енімал Хелс Гмбх Похідні азахіноліну

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050004159A1 (en) * 1999-12-13 2005-01-06 Eisai Co., Ltd. Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it
CN1893943A (zh) * 2003-10-03 2007-01-10 3M创新有限公司 吡唑并吡啶和其类似物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3204126A1 (de) * 1982-02-06 1983-08-11 Bayer Ag, 5090 Leverkusen Pyrazoloxazine, -thiazine, -chinoline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4479955A (en) * 1983-01-10 1984-10-30 Ciba-Geigy Corporation Heterocycle-fused pyrazolo[3,4-d]pyridin-3-ones as benzodiazepine receptor modulators
US4814450A (en) 1984-07-09 1989-03-21 Ciba-Geigy Corporation Certain ring-fused pyrazolo[3,4-d]-pyridin-3-one derivatives
JPS61112075A (ja) * 1984-11-05 1986-05-30 Shionogi & Co Ltd チエニルピラゾロキノリン誘導体
EP0214092A1 (en) 1985-08-08 1987-03-11 Ciba-Geigy Ag Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone
US4817450A (en) * 1987-11-30 1989-04-04 Spedco, Inc. Pressure/temperature test plug assembly
FR2695126B1 (fr) * 1992-08-27 1994-11-10 Sanofi Elf Dérivés d'acide thiényl ou pyrrolyl carboxyliques, leur préparation et médicaments les contenant.
US5334595A (en) * 1992-10-23 1994-08-02 Sterling Winthrop Inc. Pyrazoloquinolones as anticancer agents
DE69518075T2 (de) * 1994-05-24 2001-03-22 F. Hoffmann-La Roche Ag, Basel Tricyclische dicarbonylderivate
GB9716347D0 (en) 1997-08-01 1997-10-08 Merck Sharp & Dohme Therapeutic compounds
GB9716344D0 (en) * 1997-08-01 1997-10-08 Merck Sharp & Dohme Therapeutic compounds
GB9716345D0 (en) * 1997-08-01 1997-10-08 Merck Sharp & Dohme Therapeutic compounds
GB0108475D0 (en) * 2001-04-04 2001-05-23 Merck Sharp & Dohme New compounds
JP3896309B2 (ja) * 2001-07-09 2007-03-22 ファイザー株式会社 プロテインキナーゼｃ阻害物質としてのピラゾロキノリノン誘導体
WO2004055014A1 (en) * 2002-12-16 2004-07-01 Active Biotech Ab Tetracyclic immunomodulatory compounds
WO2005028474A2 (en) * 2003-05-29 2005-03-31 Millennium Pharmaceuticals, Inc. Pyrazoloquinoline derivatives as chk-1 inhibitors
US7544697B2 (en) * 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
JP2009507081A (ja) * 2005-09-07 2009-02-19 ブレインセルス，インコーポレイティド ＨＤａｃ阻害による神経発生の調整
AU2008261884A1 (en) * 2007-06-08 2008-12-18 Helicon Therapeutics, Inc. Therapeutic pyrazoloquinoline derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050004159A1 (en) * 1999-12-13 2005-01-06 Eisai Co., Ltd. Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it
CN1893943A (zh) * 2003-10-03 2007-01-10 3M创新有限公司 吡唑并吡啶和其类似物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106810550A (zh) * 2017-01-10 2017-06-09 湖南华腾制药有限公司 一种萘啶衍生物的制备方法
CN117430602A (zh) * 2023-09-26 2024-01-23 爱斯特（成都）生物制药股份有限公司 一种制备6-卤代-4-羟基[1,5]萘啶-3-甲酸酯及其衍生物的方法

Also Published As

Publication number Publication date
HK1142774A1 (en) 2010-12-17
EP2166853A4 (en) 2011-04-06
BRPI0812369A2 (pt) 2016-08-09
IL202287A0 (en) 2010-06-16
US7858614B2 (en) 2010-12-28
MX2009013197A (es) 2010-04-27
EP2166853B1 (en) 2014-05-28
US20110065692A1 (en) 2011-03-17
WO2008154447A1 (en) 2008-12-18
CA2689934A1 (en) 2008-12-18
JP2010529145A (ja) 2010-08-26
US8497262B2 (en) 2013-07-30
EP2166853A1 (en) 2010-03-31
ES2483728T3 (es) 2014-08-07
KR20100036306A (ko) 2010-04-07
US20090005365A1 (en) 2009-01-01
AU2008261803A1 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
CN101754681A (zh) 治疗用吡唑并萘啶衍生物
US8343957B2 (en) Therapeutic pyrazoloquinoline urea derivatives
JP2010529145A5 (enExample)
CN101742908A (zh) 治疗用吡唑并喹啉衍生物
HK1144892A (en) Therapeutic pyrazolonaphthyridine derivatives
HK1142774B (en) Therapeutic pyrazolonaphthyridine derivatives
US9012470B2 (en) Therapeutic 5,6,5-tricyclic analogs
HK1144891A (zh) 治疗用吡唑并喹啉衍生物
HK1142776A (en) Therapeutic pyrazoloquinoline urea derivatives
HK1142775B (en) Therapeutic pyrazoloquinoline derivatives
HK1142496B (en) Therapeutic pyrazoloquinoline urea derivatives

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1144892

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100623

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1144892

Country of ref document: HK